Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

The Application of the E-health Education on Shared Care Program for Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: E-health Education;   Other: Routine care
Sponsor:   Li-Li Chen
Recruiting - verified February 2017

FFAR Agonist on Incretins, Insulin, Lipids and Inflammation

Conditions:   Type2 Diabetes Mellitus;   Obesity
Intervention:   Dietary Supplement: Pine nut oil
Sponsor:   Odense University Hospital
Completed - verified February 2017

The Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: conventional treatment;   Other: Maltose app
Sponsors:   Qingdao Zhixin Health Technology Co., Ltd.;   H & J CRO International, Inc.
Recruiting - verified February 2017

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

Condition:   Type2 Diabetes With Depressive Mood
Interventions:   Drug: Chonline Alphoscerate;   Drug: Placebo Oral Tablet
Sponsor:   Yonsei University
Recruiting - verified February 2017

A Phase Ib Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BFKB8488A;   Other: Placebo
Sponsor:   Genentech, Inc.
Recruiting - verified February 2017

Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Interventions:   Biological: Exenatide injection(Byetta);   Biological: PB-119 injection
Sponsor:   PegBio Co., Ltd.
Completed - verified February 2017

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide 0.5 mg;   Drug: Semaglutide 1.0 mg;   Drug: Sitagliptin placebo;   Drug: Sitagliptin;   Drug: Semaglutide placebo 0.5 mg;   Drug: Semaglutide placebo 1.0 mg
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified February 2017

Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements

Condition:   Non-alcoholic Fatty Liver Disease
Intervention:   Other: diabetes
Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Recruiting - verified September 2016

Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Appointment Attendance in DM Patients

Conditions:   Appointments and Schedules;   Diabetes Mellitus, Type 2
Intervention:   Other: Mobile phone text message reminder
Sponsors:   The University of Hong Kong;   Hospital Authority, Hong Kong
Recruiting - verified February 2017

Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients

Conditions:   Cancer;   Colon Cancer;   Breast Cancer;   Malignant Lymphoma
Intervention:   Drug: Chemotherapy
Sponsors:   National Cancer Center, Korea;   SMG-SNU Boramae Medical Center
Recruiting - verified February 2017

Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Drug: Mifepristone 600 mg daily;   Drug: Placebo
Sponsor:   Charles Drew University of Medicine and Science
Recruiting - verified February 2017

Continuous Multiple Dose PB-119 Injection in Health Volunteers

Condition:   Type2 Diabetes Mellitus
Intervention:   Biological: PB-119 injection
Sponsor:   PegBio Co., Ltd.
Completed - verified February 2017

App-technology to Increase Physical Activity Among Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Exercise
Intervention:   Behavioral: App-technology to increase physical activity
Sponsors:   Karolinska Institutet;   Stockholm County Council, Sweden
Recruiting - verified February 2017

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: Empagliflozin (oral);   Drug: Glimepiride (oral)
Sponsor:   Intarcia Therapeutics
Not yet recruiting - verified February 2017

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

Conditions:   Atherosclerotic Cardiovascular Disease;   Symptomatic Atherosclerosis;   Type2 Diabetes;   Familial Hypercholesterolemia
Interventions:   Drug: Inclisiran;   Drug: Evolocumab
Sponsor:   The Medicines Company
Not yet recruiting - verified February 2017

Resistant Starch, Gut Bacteria and Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Pre Diabetes
Intervention:   Dietary Supplement: SymbioIntest
Sponsors:   University of Hohenheim;   Institut für Mikroökologie GmbH
Recruiting - verified February 2017

Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes

Condition:   Type2 Diabetes
Intervention:   Procedure: Double-balloon enteroscopy (DBE) with biopsy retrieval
Sponsor:   University Hospital, Gentofte, Copenhagen
Completed - verified February 2017

Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and Metformin-treated Type 2 Diabetes

Condition:   Overweight and Obesity
Interventions:   Device: Gelesis200;   Device: Placebo
Sponsor:   Gelesis, Inc.
Not yet recruiting - verified February 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind

Conditions:   Diabetes Mellitus;   Alzheimer Dementia
Intervention:   Drug: 18F-THK-5351
Sponsors:   Columbia University;   National Institute on Aging (NIA)
Not yet recruiting - verified February 2017

Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo;   Drug: Liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Glargine U300 Hospital Trial

Condition:   Type 2 Diabetes
Interventions:   Drug: Glargine U300;   Drug: Glargine U100;   Drug: Glulisine Insulin
Sponsor:   Emory University
Not yet recruiting - verified February 2017

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Obese Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: bimagrumab;   Other: placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2017

A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified February 2017

Metformin in Intrahepatic Cholestasis of Pregnancy

Conditions:   Intrahepatic Cholestases;   Pregnancy Complications
Interventions:   Drug: Metformin;   Drug: Ursodeoxycholic Acid
Sponsors:   Epsom and St Helier University Hospitals NHS Trust;   King's College Hospital NHS Trust;   Medway NHS Foundation Trust
Not yet recruiting - verified December 2016

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified February 2017

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Conditions:   Type2 Diabetes;   Cardiovascular Diseases
Interventions:   Drug: Dapagliflozin;   Drug: Glimepiride
Sponsors:   University of Michigan;   AstraZeneca
Recruiting - verified February 2017

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2017

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Glimepiride;   Drug: Empagliflozin
Sponsor:   Yonsei University
Recruiting - verified February 2017

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Conditions:   Metabolism and Nutrition Disorder;   Obesity
Interventions:   Drug: Liraglutide 3.0 mg;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified February 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Drug-naïve Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified February 2017

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified February 2017

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Linagliptin Add-on to Insulin Background Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin;   Drug: background therapy
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Arming Health: Can Breaking up Restful Sitting Time With Upper Body Contractile Activity Regulate Metabolic Health.

Condition:   Diabetes
Interventions:   Other: Prolonged Sitting;   Other: Light arm ergometry breaks
Sponsors:   University of Leicester;   National Institute for Health Research, United Kingdom;   National Health Service, United Kingdom
Completed - verified August 2016

Effect of Valedia on Glucose and Lipid Homeostasis on Subjects With Prediabetes

Conditions:   Prediabetes;   Type 2 Diabetes;   Hypertriglyceridemia;   Obesity;   Disease;   Insulin Resistance
Interventions:   Dietary Supplement: Valedia;   Dietary Supplement: Placebo
Sponsors:   Valbiotis;   BioFortis;   Institut Pasteur de Lille
Recruiting - verified February 2017

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Effect of DMR Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Conditions:   Diabetes Mellitus, Type 2;   Noninsulin-Dependent Diabetes Mellitus
Interventions:   Procedure: DMR Procedure;   Procedure: Sham Procedure
Sponsor:   Fractyl Laboratories, Inc.
Recruiting - verified February 2017

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Shared Decision Making
Sponsors:   AstraZeneca;   Brigham Women's Health
Recruiting - verified February 2017

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Low dosE GlibENclamide in Diabetes Part A

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Glibenclamide
Sponsors:   University of Oxford;   Oxford University Hospitals NHS Trust
Active, not recruiting - verified February 2017

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2017

Pediatric Obesity and the Infant Microbiome

Condition:   Pediatric Obesity
Intervention:  
Sponsor:   University of Florida
Recruiting - verified February 2017

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Condition:   Hypertension
Intervention:   Drug: CS-3150
Sponsor:   Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified February 2017

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

Condition:   T2DM With NAFLD
Interventions:   Drug: AZD4076;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified February 2017

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide;   Drug: Albiglutide
Sponsors:   GlaxoSmithKline;   Wake Forrest Baptist Health
Recruiting - verified February 2017

A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Conditions:   Healthy;   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: LY3298176;   Drug: Placebo;   Drug: Dulaglutide
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2017

The Efficacy and Safety of Chinese Herbal Medicine YH1 as Add-On Medication in Poorly Controlled Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: YH1;   Drug: placebo
Sponsor:   Chang Gung Memorial Hospital
Recruiting - verified March 2016

Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients

Condition:   Neuropathology
Intervention:   Device: Exams
Sponsor:   Groupe Hospitalier Paris Saint Joseph
Recruiting - verified May 2016

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Device: Auto-injector
Sponsor:   GlaxoSmithKline
Completed - verified February 2017

Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics

Conditions:   Healthy;   Type 2 Diabetes Mellitus
Interventions:   Drug: GMC-252-L-Lysine Salt;   Other: Placebo
Sponsors:   Genmedica Therapeutics S.L.;   Simbec Research
Recruiting - verified February 2017

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified February 2017

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: alpha-glucosidase inhibitors;   Drug: DPP-4 inhibitors;   Drug: meglitinides;   Drug: SGLT-2 inhibitors;   Drug: sulfonylurea;   Drug: thiazolidinediones
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Conditions:   Diabetes Mellitus, Type 2;   Impaired Glucose Tolerance (IGT);   Impaired Fasting Glucose (IFG)
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Pioglitazone;   Drug: Metformin
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association;   AstraZeneca
Recruiting - verified February 2017

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lyophilized albiglutide DCC pen injector;   Drug: Lyophilized albiglutide DCC pen injector matching placebo;   Drug: Albiglutide liquid auto-injector;   Drug: Albiglutide liquid auto-injector matching placebo
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified February 2017

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: Dulaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified February 2017

Study of Carrageenan's Effect on Insulin Resistance in Humans

Conditions:   Diabetes Mellitus, Type 2;   Insulin Resistance
Interventions:   Dietary Supplement: Carrageenan;   Dietary Supplement: Placebo
Sponsor:   University Hospital Tuebingen
Active, not recruiting - verified February 2017

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Conditions:   Diabetes;   Wound Infection;   Healthy Volunteers
Interventions:   Drug: Tedizolid;   Procedure: Microdiaylsis Catheter Insertion
Sponsors:   Hartford Hospital;   Merck Sharp & Dohme Corp.
Recruiting - verified February 2017

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Conditions:   Diabetes;   Wound Infection;   Healthy Volunteers
Interventions:   Drug: Ceftolozane/tazobactam;   Procedure: Microdialysis Catheter Insertion
Sponsors:   Hartford Hospital;   Merck Sharp & Dohme Corp.
Recruiting - verified February 2017

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Completed - verified February 2017

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury

Conditions:   Spinal Cord Injury;   Paraplegia;   Tetraplegia
Intervention:   Device: Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)
Sponsor:   University of Manitoba
Recruiting - verified February 2017

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified February 2017

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Completed - verified February 2017

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin, Onglyza;   Drug: Dapagliflozin, Farxiga;   Drug: Glargine insulin;   Drug: Metformin XR
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified February 2017

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin;   Drug: Sulfonylurea
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2017

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Biological: MEDI-4166;   Biological: Placebo
Sponsor:   MedImmune LLC
Active, not recruiting - verified February 2017

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified February 2017

Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption

Condition:   Glucose Metabolism Disorder
Interventions:   Other: Oral glucose tolerance test (OGTT);   Other: Diet soda containing aspartame only
Sponsor:   Rockefeller University
Recruiting - verified February 2017

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified February 2017

Effect of Ramadan Fasting on Ovulation and Insuline Resistance in Patients With PCOS

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsor:   Ain Shams University
Recruiting - verified February 2017

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Active, not recruiting - verified February 2017

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Regular Human Insulin;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Novo Nordisk A/S;   Medtronic;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2017

Strength Training Regimen for Normal Weight Diabetics

Condition:   Diabetes Mellitus
Intervention:   Behavioral: Exercise Intervention
Sponsors:   Stanford University;   Pennington Biomedical Research Center
Recruiting - verified February 2017

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Terminated - verified February 2017

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Condition:   Physical Activity
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   Christopher Bell;   AstraZeneca
Recruiting - verified February 2017

Mechanisms of Weight Loss With SGLT2 Inhibition

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Janssen Scientific Affairs, LLC
Recruiting - verified February 2017

Saxagliptin and Acute Myocardial Infarction:Effects on Platelet Function

Condition:   Platelet Aggregation During Acute Myocardial Infarction
Interventions:   Drug: saxagliptin;   Drug: placebo
Sponsors:   University of Sao Paulo General Hospital;   InCor Heart Institute
Recruiting - verified January 2017

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified February 2017

A Comparison of Exenatide and Insulin Glargine

Condition:   Type 2 Diabetes
Interventions:   Drug: exenatide;   Drug: Insulin glargine
Sponsor:   The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Completed - verified February 2017

Hormonal Mechanisms of Sleep Restriction

Condition:   Insulin Resistance
Interventions:   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: Testosterone;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo
Sponsor:   Los Angeles Biomedical Research Institute
Active, not recruiting - verified March 2016

Glycemic and Insulinemic Response With Different Sources of Soluble Fiber in Patients Type 2 Diabetes Mellitus

Conditions:   Dietary Modification;   Diabetes Mellitus Type 2;   Insulin Tolerance;   Diabetic Blood Glucose Monitoring
Interventions:   Other: HFD Meal: High fiber from food;   Dietary Supplement: HFS Meal: High fiber from supplement;   Other: UF Meal: usual amount of fiber
Sponsors:   Hospital de Clinicas de Porto Alegre;   Federal University of Rio Grande do Sul;   Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Completed - verified February 2017

A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Conditions:   Diabetes;   Diabetes Mellitus Type 2
Interventions:   Drug: Liraglutide;   Drug: Metformin;   Drug: Placebo;   Drug: NNC0090-2746
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Forxiga Tablets Specific Clinical Experience Investigation for Elderly

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Completed - verified February 2017

Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood

Condition:   Obesity
Interventions:   Other: obese patients;   Other: diabetic patients;   Other: patients free of obesity and diabetes;   Other: patients free type 2 diabetes
Sponsor:   University Hospital, Toulouse
Recruiting - verified February 2017

Hypoxia and Exercise in the Elderly

Condition:   Elderly Persons
Interventions:   Other: Hypoxic exercise;   Other: Normoxic Exercise
Sponsors:   Hannover Medical School;   German Diabetes Center
Recruiting - verified February 2016

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: ipragliflozin;   Drug: placebo
Sponsor:   Astellas Pharma Inc
Completed - verified February 2017

Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II

Condition:   Diabetes Mellitus Type II
Intervention:   Drug: e.-coli-nissle
Sponsors:   GWT-TUD GmbH;   Ardeypharm GmbH
Completed - verified August 2015

Clinical Trial for PB-119 in Healthy Subjects (Phase I)

Condition:   Type II Diabetes
Intervention:   Drug: PB-119
Sponsor:   PegBio Co., Ltd.
Completed - verified February 2017

Laser Treatment for Onychomycosis in Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Onychomycosis
Interventions:   Device: Laser Treatment YAG laser;   Drug: Standard Treatment (control group) terbinafine hydrochloride tablets
Sponsors:   BCDiabetes.Ca;   BritaMed, Inc.
Not yet recruiting - verified February 2017

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2017

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Incretin and KATP Channels

Condition:   Healthy Subjects
Intervention:   Other: Intradermal injections of GLP-1 and its analogues
Sponsors:   Katarina Kos;   University of Exeter
Terminated - verified February 2017

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified February 2017

Regulating Efficacy and Wellness in Diabetes

Conditions:   Diabetes Type 2;   Metabolic Syndrome
Intervention:   Behavioral: Walking exercise
Sponsors:   University of Illinois at Urbana-Champaign;   National Institute on Aging (NIA)
Completed - verified February 2017

Closed-loop Insulin Delivery in the General Ward

Condition:   Diabetes Mellitus
Interventions:   Device: Fully Automated Closed-Loop Insulin Delivery;   Device: Conventional insulin therapy
Sponsors:   University of Cambridge;   Cambridge University Hospitals NHS Foundation Trust;   Central Manchester University Hospitals NHS Foundation Trust;   University Hospital Inselspital, Berne
Recruiting - verified February 2017

GLP-1 and Microvascular Function in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Liraglutide;   Other: diet;   Drug: Aspirin
Sponsors:   Royal Devon and Exeter NHS Foundation Trust;   University of Exeter
Completed - verified February 2017

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: metformin;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: isophane human insulin;   Drug: insulin
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified February 2017

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2017

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: glyburide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 30;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: aleglitazar+metformin;   Drug: placebo+metformin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2017

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2017

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart 50;   Drug: biphasic human insulin 50
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

The Effect of Exercise on Hepatic Glucose Metabolism

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Behavioral: Aerobic exercise
Sponsor:   Vanderbilt University
Completed - verified February 2017

Barriers to Physical Activity in People With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Placebo Attention Control;   Other: Supervised Exercise Training
Sponsors:   University of Colorado, Denver;   Colorado Clinical & Translational Sciences Institute
Recruiting - verified February 2017

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Completed - verified February 2017

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: glyburide
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Fibrosis a New Pathological Actor in Adipose Tissue

Conditions:   Obesity;   Metabolic Diseases;   Fibrosis;   Body Weight
Intervention:   Procedure: biopsy
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified February 2017

Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: insulin NPH
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2017

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2017

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Placebo to vildagliptin;   Drug: vildagliptin;   Drug: Metformin
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting - verified February 2017

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: biphasic human insulin
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: repaglinide
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Relationship Between Gestational Diabetes and Type 2 Diabetes

Conditions:   Gestational Diabetes;   Type 2 Diabetes
Intervention:  
Sponsor:   Laval University
Active, not recruiting - verified February 2017

Phase 4 Study in the Elderly Patients With T2DM

Conditions:   Type 2 Diabetes Mellitus;   Elderly
Interventions:   Drug: Vildagliptin;   Drug: "Usual Care"
Sponsor:   Novartis
Completed - verified February 2017

Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Vildagliptin;   Drug: Placebo
Sponsor:   Novartis
Completed - verified February 2017

Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Vildagliptin;   Drug: Placebo
Sponsor:   Novartis
Completed - verified February 2017

Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myocardial Scar in Subclinical Coronary Atherosclerosis

Conditions:   Type 2 Diabetes Mellitus;   Coronary Atherosclerosis
Intervention:   Drug: Iobitridol
Sponsor:   Guerbet
Active, not recruiting - verified February 2017

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: vildagliptin/metformin
Sponsor:   Novartis
Completed - verified February 2017

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Janssen Research & Development, LLC
Completed - verified June 2013

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified February 2017

Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)

Condition:   Nonalcoholic Fatty Liver Disease
Intervention:  
Sponsor:   Vanderbilt University
Enrolling by invitation - verified February 2017

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

Conditions:   Diabetes Mellitus Type 1;   Diabetes Mellitus Type 2
Intervention:   Drug: Sitagliptin (Januvia)
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified January 25, 2017

Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: biphasic human insulin 30;   Drug: insulin NPH
Sponsor:   Novo Nordisk A/S
Terminated - verified February 2017

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: semaglutide;   Drug: placebo;   Drug: placebo;   Drug: placebo;   Drug: placebo;   Drug: placebo;   Drug: liraglutide;   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin aspart;   Drug: human insulin
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin detemir;   Drug: insulin aspart;   Device: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Initiation of Insulin Aspart in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: metformin;   Drug: glicazide
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: repaglinide;   Drug: Glurenorm®;   Drug: Glucobay®
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

Conditions:   Microalbuminuria;   Proteinuria
Intervention:   Drug: valsartan
Sponsor:   Novartis
Completed - verified February 2017

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: vildagliptin + metformin
Sponsor:   Novartis
Completed - verified February 2017

Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone

Condition:   Type 2 Diabetes
Intervention:   Drug: Nateglinide
Sponsor:   Novartis Pharmaceuticals
Completed - verified February 2017

A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: NNC 55-0414
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Vildagliptin
Sponsor:   Novartis
Completed - verified February 2017

A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Vildagliptin
Sponsor:   Novartis
Completed - verified February 2017

Family Investigation of Nephropathy and Diabetes (F.I.N.D.)

Conditions:   Diabetic Nephropathy;   Diabetes Mellitus;   Diabetic Kidney Disease;   Albuminuria
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2, 2017

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: biphasic insulin aspart;   Drug: insulin glargine;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Completed - verified February 2017

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: vildagliptin;   Drug: pioglitazone
Sponsor:   Novartis
Completed - verified February 2017